Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
McKesson
Moodys
Mallinckrodt
QuintilesIMS
Chubb
Baxter
Medtronic
Covington

Generated: November 15, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022225

« Back to Dashboard

NDA 022225 describes BRIDION, which is a drug marketed by Organon Sub Merck and is included in one NDA. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the BRIDION profile page.

The generic ingredient in BRIDION is sugammadex sodium. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the sugammadex sodium profile page.
Summary for 022225
Tradename:BRIDION
Applicant:Organon Sub Merck
Ingredient:sugammadex sodium
Patents:3
Formulation / Manufacturing:see details
Generic Entry Opportunity Date for 022225
Generic Entry Date for 022225*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 022225
Ingredient-typegamma-Cyclodextrins
Suppliers and Packaging for NDA: 022225
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
BRIDION sugammadex sodium SOLUTION;INTRAVENOUS 022225 NDA Merck Sharp & Dohme Corp. 0006-5423 0006-5423-12 10 VIAL, SINGLE-DOSE in 1 CARTON (0006-5423-12) > 2 mL in 1 VIAL, SINGLE-DOSE (0006-5423-02)
BRIDION sugammadex sodium SOLUTION;INTRAVENOUS 022225 NDA Merck Sharp & Dohme Corp. 0006-5423 0006-5423-15 10 VIAL, SINGLE-DOSE in 1 CARTON (0006-5423-15) > 5 mL in 1 VIAL, SINGLE-DOSE (0006-5423-05)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAVENOUSStrengthEQ 500MG BASE/5ML (EQ 100MG BASE/ML)
Approval Date:Dec 15, 2015TE:RLD:Yes
Regulatory Exclusivity Expiration:Dec 15, 2020
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:➤ Try a Free TrialPatent Expiration:Jan 27, 2021Product Flag?Substance Flag?Delist Request?
Patented Use:REVERSAL OF NEUROMUSCULAR BLOCKAGE INDUCED BY ROCURONIUM BROMIDE OR VECURONIUM BROMIDE
Patent:➤ Try a Free TrialPatent Expiration:Aug 7, 2020Product Flag?Substance Flag?Delist Request?
Patented Use:REVERSAL OF NEUROMUSCULAR BLOCKAGE INDUCED BY ROCURONIUM BROMIDE OR VECURONIUM BROMIDE

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
McKesson
Healthtrust
Johnson and Johnson
AstraZeneca
Express Scripts
Federal Trade Commission
Teva
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.